Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-45.65M |
| Operating Margin | 0.00% |
| Return on Equity | -35.20% |
| Return on Assets | -18.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.82 |
| Price-to-Book | 1.27 |
| Price-to-Sales (TTM) | 2.11 |
| EV/Revenue | 0.739 |
| EV/EBITDA | 2.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $57.30M |
| Float | $46.26M |
| % Insiders | 0.62% |
| % Institutions | 78.66% |
Volatility is currently expanding